Intervention not reported
Serious adverse events (number) · people with acute pancreatitis
1 finding from 1 review
- 0.86 [0.68, 1.07]12 studies · 716 participantsVery low
Findings
What do systematic reviews say?
1,004 questions · 1,019 findings · 269 reviews
No studies found 333 · 32.7%GRADE not reported 106 · 10.4%Very low 313 · 30.7%Low 189 · 18.5%Moderate 66 · 6.5%High 12 · 1.2%
Colchicine vs no intervention
Serious adverse events (number) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
- Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Insulin plus glucagon vs no intervention
Serious adverse events (number) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
- Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Propylthiouracil vs no intervention
Serious adverse events (number) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
- Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Glucocorticosteroids vs no intervention
Serious adverse events (number) · participants with severe alcoholic hepatitis
The review found no eligible studies for this question.
1 finding from 1 review
- Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Pentoxifylline vs no intervention
Serious adverse events (number) · participants with severe alcoholic hepatitis
The review found no eligible studies for this question.
1 finding from 1 review
- Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Anabolic steroids vs no intervention
Serious adverse events (number) · alcohol‐related disorders (others)
The review found no eligible studies for this question.
1 finding from 1 review
- Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Glucocorticosteroids vs no intervention
Serious adverse events (number) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
- Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Antioxidants vs no intervention
Serious adverse events (number) · alcohol‐related disorders (others)
The review found no eligible studies for this question.
1 finding from 1 review
- Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Colchicine vs no intervention
Serious adverse events (number) · alcohol‐related disorders (others)
The review found no eligible studies for this question.
1 finding from 1 review
- Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Propylthiouracil vs no intervention
Serious adverse events (number) · alcohol‐related disorders (others)
The review found no eligible studies for this question.
1 finding from 1 review
- Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Pentoxifylline vs no intervention
Serious adverse events (number) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
- Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Lifestyle interventions vs placebo or usual care
Adverse events – musculoskeletal · weight reduction in obesity to improve survival in women with endometrial cancer
It is very uncertain whether summary of findings table ‐ Lifestyle intervention changes adverse events – musculoskeletal compared with usual care compared to placebo (very low certainty).
1 finding from 1 review
- Interventions for weight reduction in obesity to improve survival in women with endometrial cancer 2023 · Cochrane Headline outcomes onlyRR 19.03 [1.17, 310.52]8 studies · 315 participantsVery low
Intravenous preparations vs oral preparations
Withdrawals due to adverse events · IBD patients
Intravenous preparations may leads to lower withdrawal due to adverse events compared with oral preparations (low certainty).
1 finding from 1 review
- Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes onlyRR 0.39 [0.2, 0.74]5 studies · 927 participantsLow
Mindfulness with cognitive behavioural therapy (CBT) vs no treatment (both groups received standard medical therapy)
Withdrawals due to adverse events · people with inflammatory bowel disease
1 finding from 1 review
- Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 66 participantsVery low
Enteric‐release glyceryl trinitrate vs placebo
Withdrawals due to adverse events · people with Crohn's disease
It is very uncertain whether enteric‐release glyceryl trinitrate changes withdrawal due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
- Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease 2021 · Cochrane Headline outcomes onlyRR 3.18 [0.94, 10.76]1 study · 70 participantsVery low
100 mg olorinab 3 times/day vs 25 mg olorinab 3 times/day
Withdrawals due to adverse events · people with Crohn's disease
1 finding from 1 review
- Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 14 participantsVery low
Yoga vs no treatment (both groups received standard medical therapy)
Withdrawals due to adverse events · people with inflammatory bowel disease
1 finding from 1 review
- Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 100 participantsVery low
tDCS vs sham stimulation
Withdrawals due to adverse events · people with inflammatory bowel disease
1 finding from 1 review
- Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 20 participantsLow
Low FODMAP diet vs sham diet
Withdrawals due to adverse events · people with inflammatory bowel disease
It is very uncertain whether low FODMAP diet changes withdrawal due to adverse events compared with sham diet (very low certainty).
1 finding from 1 review
- Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease 2021 · Cochrane Headline outcomes onlyRR 1.85 [0.18, 19.19]1 study · 52 participantsVery low